NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Does MGMT methylated REALLY need TERT methylated to
have an effect

Conclusions:
The prognostic value of TERT promoter mutation may be modulated by MGMT methylation status.

Not all MGMT-methylated GBM patients may benefit from TMZ;

it is possible that only TERT-mutated GBM with MGMT methylation, in particular, may respond.

2020 - Sept
The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis

https://pubmed.ncbi.nlm.nih.gov/32957941/

TERT and DCVAX
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422384/


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337853/

How Do we Find Patients Who Will Respond?

Dr. Liau has long experience with dendritic cell cancer vaccines. She injected her first patient in 1999. In the phase 1/2 trials of DCVax-L which were the basis for the planning of the phase 3 DCVax-L trial, about 30% of patients are still alive. The question is how can these patients who apparently are so responsive to DCVax-L be identified prospectively?

Glioblastomas are Heterogeneous

She says that glioblastomas are heterogeneous as the disease can emanate from quite different genetic mutations which may determine which subset(s) of patients who benefit. She cited mesenchymal vs. proneural. MGMT, IDH, 1p19q, TERT as examples. There are also other predictors such as the degree of resection. The challenge is to understand what biomarkers characterize the 20% to 30% of patients who receive great benefit?

https://smithonstocks.com/northwest-biotherapeutics-dcvax-l-viewed-through-the-eyes-of-dr-linda-liau-lead-investigator-on-the-phase-3-trial-of-dcvax-l-nwbo-0-35-buy/


Management of glioblastoma: State of the art and future directions
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21613